The ruling is a significant win for The EVERY Company, which can now continue its operations without the immediate threat of legal challenges from Onego Bio. For Onego, the decision leaves its business strategy uncertain, as it had sought clarity on its ability to operate without infringing on EVERY's patents. The case highlights the complexities of intellectual property disputes in the emerging field of precision fermentation, where companies are vying for technological dominance. The decision also leaves open the possibility of future legal action, as the court did not rule on the validity of EVERY's patent.